Deutsche Bank initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy rating and a price target of $40.00. Analyst Alethia Young estimates $4 billion in potential sales from Alnylam's RNA tech platform.
"Alnylam is an early stage company that uses a technology called RNA interference that occurs naturally in the body to silence problematic genes in diseases that were previously deemed un-druggable. We believe Alnylam has the chance to unlock significant long-term value as they commercialize their assets in the clinic during 2017 and beyond, leading to $4B+ in unadjusted sales," said Young.
Well now look I think first and foremost the next several weeks are going to be an important set of data points for the company. We’ve got data from our complement program that will come out middle of the month of June. We’ve got data from our particular or two program by the end of June and data from our affiliate program, sort of end of June early July and then we also have an R&D day that’s being held on July 11 that I hope everybody can come to.
My comments: PCYC is a $4 billion sales potential company and PCYC owns 50% and JNJ owns
the other 50%, ALNY owns 100% of the $4 billion sales potential.